Intra-breath oscillometry is a sensitive test for assessing disease control in adults with severe asthma

Author(s):  
Joseane Chiabai ◽  
Frederico Orlando Friedrich ◽  
Morgana Thaís Carollo Fernandes ◽  
Faradiba Sarquis Serpa ◽  
Marcos Otávio Brum Antunes ◽  
...  
Author(s):  
V.C.H. dos Santos ◽  
M.A.F. Moreira ◽  
A.V. da Rosa ◽  
S.M. Sobragi ◽  
C.A.J. da Silva ◽  
...  

2013 ◽  
Vol 50 (8) ◽  
pp. 884-890 ◽  
Author(s):  
Michael A. Yonas ◽  
Anna L. Marsland ◽  
Chetachi A. Emeremni ◽  
Charity G. Moore ◽  
Fernando Holguin ◽  
...  

2020 ◽  
Author(s):  
Paloma Campo ◽  
jose gregorio Soto campos ◽  
Ana Moreira Jorge ◽  
Santiago Quirce ◽  
Alicia Padilla ◽  
...  

Allergy ◽  
2020 ◽  
Author(s):  
Paloma Campo ◽  
Gregorio Soto Campos ◽  
Ana Moreira ◽  
Santiago Quirce ◽  
Alicia Padilla‐Galo ◽  
...  

Vaccines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 853
Author(s):  
Marco Caminati ◽  
Gabriella Guarnieri ◽  
Veronica Batani ◽  
Elena Scarpieri ◽  
Anita Finocchiaro ◽  
...  

Background: COVID-19 vaccination has been recommended for severe asthmatics. We aimed to evaluate the safety, tolerability, and impact on disease control and patient’s quality of life of the mRNA SARS-CoV-2/COVID-19 vaccine in severe asthma patients regarding biologic treatment. Methods: Severe asthmatic patients regularly managed by two big allergy and respiratory referral centers were offered to undergo Pfizer COVID 19 vaccination at the hospital site. Patients filled in an adverse events questionnaire after the first and second dose, as well as the Asthma Control Test (ACT) and Asthma Quality of Life Questionnaire (AQLQ). Results: Overall, 253 patients were vaccinated; only 16 patients refused. No serious events were detected. Less than 20% of patients reported side effects, most of which were classified as very common side effects. No differences were reported according to the ongoing biologic drug. A significant improvement in both ACT and AQLQ was observed between the first and the second dose administration. Conclusions: Our data confirm the optimal safety and tolerability profile of mRNA SARS- CoV-2/COVID-19 in severe asthma patients on biologic treatment, as well as their positive attitude towards COVID-19 vaccination. The negligible proportion of patients reporting side effects and the absence of asthma exacerbations are relevant to support the COVID-19 vaccination campaign in severe asthma patients worldwide.


Author(s):  
Pierluigi Paggiaro ◽  
Federico L. Dente ◽  
Giulia Spoletini ◽  
Lorenza Melosini ◽  
Federica Novelli ◽  
...  

1975 ◽  
Vol 39 (2) ◽  
pp. 102-105
Author(s):  
Pinkham ◽  
G Ori ◽  
SH Wei ◽  
CA Full ◽  
FM Parkins

2019 ◽  
Vol 28 (3) ◽  
pp. 1363-1370 ◽  
Author(s):  
Jessica Brown ◽  
Katy O'Brien ◽  
Kelly Knollman-Porter ◽  
Tracey Wallace

Purpose The Centers for Disease Control and Prevention (CDC) recently released guidelines for rehabilitation professionals regarding the care of children with mild traumatic brain injury (mTBI). Given that mTBI impacts millions of children each year and can be particularly detrimental to children in middle and high school age groups, access to universal recommendations for management of postinjury symptoms is ideal. Method This viewpoint article examines the CDC guidelines and applies these recommendations directly to speech-language pathology practices. In particular, education, assessment, treatment, team management, and ongoing monitoring are discussed. In addition, suggested timelines regarding implementation of services by speech-language pathologists (SLPs) are provided. Specific focus is placed on adolescents (i.e., middle and high school–age children). Results SLPs are critical members of the rehabilitation team working with children with mTBI and should be involved in education, symptom monitoring, and assessment early in the recovery process. SLPs can also provide unique insight into the cognitive and linguistic challenges of these students and can serve to bridge the gap among rehabilitation and school-based professionals, the adolescent with brain injury, and their parents. Conclusion The guidelines provided by the CDC, along with evidence from the field of speech pathology, can guide SLPs to advocate for involvement in the care of adolescents with mTBI. More research is needed to enhance the evidence base for direct assessment and treatment with this population; however, SLPs can use their extensive knowledge and experience working with individuals with traumatic brain injury as a starting point for post-mTBI care.


Sign in / Sign up

Export Citation Format

Share Document